FILIP1-associated neuromuscular disorder and phenotypic blending due to paternal UPD6

Le résumé fourni par la source

We read with interest the study of Roos et al.1 describing a novel syndrome due to disruption of FILIP1 (filamin A interacting protein 1). Together with the concurrent reports by Schnabel et al.2 and Al-Kasbi et al.,3 10 affected individuals from 7 families have now been described showing combinations of contractures, microcephaly, facial dysmorphism and intellectual disability/developmental delay. Novel disease–gene associations are increasingly limited to ultra-rare conditions and in some cases take several years to replicate. We provide an update on Family A from Roos et al.1 which includes description of the FILIP1-associated phenotype in adulthood. Using data from the 100 000 Genomes Project (100kGP) and the NHS Genomic Medicine Service (GMS), two newly identified families are also described, including one individual where the nonsense FILIP1 variant was homozygous due to uniparental disomy (UPD) of chromosome 6. Mapping of recessive traits through the identification of large regions of homozygosity (ROHs) in the genome of affected individuals is a critical tool in human genetics.4 Although most often detected in consanguineous families, where they are spread across the genome, ROHs can also occur due to UPD, where the ROH is restricted to a single chromosome. We performed an exploratory ‘differential ROH’ analysis in 11 507 unsolved patients from the 100kGP (v12 release) to detect UPD (Supplementary material). Plotting the difference in size against the ratio between the largest and second largest ROHs (Fig. 1A) identified three outliers. The first two involved full chromosome isodisomy of chromosomes 1 and 4, respectively. These chromosomes have not been linked to known imprinting disorders, and no strong candidate variants on these chromosomes were identified. Differential ROH analysis in our two families identifies biallelic variants in FILIP1. (A) Exploratory ROH analysis in patients from the 100k Genomes Project identified three likely cases of UPD involving chromosomes 1, 4, and 6 where a single large ROH region was detected. (B) Plots of ROH in descending size order by chromosome in Families 1 and 2. Family 1 has a single large ROH due to UPD6, whereas Family 2 has multiple ROH on different chromosomes, in keeping with consanguinity. The third outlier (Family 1) was an 11-year-old, born to unrelated white British parents and recruited to the 100kGP under the normalised specific disease ‘arthrogryposis’. Initial analysis using 115 genes on the arthrogryposis panel v2.29 (https://panelapp.genomicsengland.co.uk) and five related panels did not identify any variants of significance. Our differential scan of large ROHs highlighted a 98.7 Mb region on chromosome 6. The next largest ROH was <2.5 Mb in size (Fig. 1B; Supplementary Table 1). Analysis of 210 414 high-quality SNVs confirmed the ROH was due to paternal isodisomy, with heterodisomy across the remainder of this 171 Mb chromosome (Supplementary Figs 1 and 2). A clinical diagnosis of paternal UPD6 had previously been confirmed using a panel of microsatellites. UPD6pat is linked to intrauterine growth retardation and transient neonatal diabetes mellitus type 1 (MIM #601410). However, additional clinical features included lower limb joint contractures, rocker bottom feet, posteriorly rotated ears, umbilical hernia, shoulder-girdle muscle atrophy, syndactyly, bilateral cryptorchidism, reduced palmar skin folds, neck pterygia, pectus carinatum and a narrow chest (Supplementary Table 2). A paediatric neurology assessment considered that these features were in keeping with reduced foetal movements associated with oligohydramnios or a multiple pterygium syndrome. Muscle biopsy was considered, but not felt to be clinically indicated in the absence of muscle weakness or features indicative of neurogenic or myopathic arthrogryposis. As these features would not be explained by UPD6pat, the family was recruited to the 100kGP. Uniparental disomy can unmask recessive alleles, and so all six rare homozygous variants on chromosome 6 (Supplementary Fig. 3) categorized as TIER3 by the Genomics England pipeline (https://doi.org/10.6084/m9.figshare.4530893.v7) were reviewed. This yielded NM_015687.5(FILIP1):c.2152C>T, p.(Arg718Ter) as the most likely causal candidate. This variant has a CADD score of 37 and is in gnomAD v4.0.0 at a global allele frequency of 142/1,563,902, but never in the homozygous state. No homozygous loss-of-function variants in FILIP1 are present in gnomAD v4.0.0 or in UK Biobank (https://afb.ukbiobank.ac.uk; accessed March 2024). Of the other five candidates, only NM_000500.9(CYP21A2):c.293-4G>A and NM_002526.4(NT5E):c.1118T>G involved OMIM-morbid autosomal-recessive genes (www.omim.org). CYP21A2 is linked to congenital adrenal hyperplasia due to 21-hydroxylase deficiency (MIM #201910), whilst NT5E is linked to calcification of joints/arteries (MIM #211800). These conditions did not fit the clinical picture (Fig. 2A–C), and the CYP21A2 variant is listed in ClinVar as likely benign (VCV000256290.6). Given the new disease association reported recently,1-3 c.2152C>T was interpreted as likely pathogenic, based on PVS1_strong, PM2_moderate and PM3_supporting using the ACMG guidelines.5 Polymerase chain reaction (PCR)-Sanger validation was performed by the NHS clinical laboratory to confirm this finding (Supplementary Fig. 4). Photos of individuals from families 1 and 3. Pictures of the proband from Family 1 show (A) webbing of the fingers, camptodactyly and digital contractures, (B) pectus carinatum and (C) narrow chest with neck webbing. For Family 3, pictures show fifth finger contractures (D) for the father and (E) for the proband. (F) The proband in F3 also has slightly flat feet. By searching for other families with biallelic truncating variants in FILIP1, we identified Family 2, which comprised two sisters recruited to the 100kGP under the indications of congenital myopathy and intellectual disability. Additional clinical features included flexion contractures, scoliosis, facial hypotonia and high arched palate. Both siblings were found to be carriers of a maternally inherited NM_004006.3(DMD):c.8713C>T, p.(Arg2905Ter) alteration (Supplementary Fig. 5), not felt to be fully causative of their phenotype. Specifically, the DMD variant was inherited from their asymptomatic mother, the older sister showed no evidence of skewed X-inactivation in lymphocytes based upon methylation sensitive analysis of the polymorphic repeat in exon 1 of the human androgen receptor, and there was no abnormality of dystrophin expression on muscle biopsy. Multiple ROHs were identified (Fig. 1B), which included a 15.0 Mb segment spanning FILIP1, shared with the affected elder sister. Both sisters were homozygous for a nonsense variant NM_015687.5(FILIP1):c.169C>T, p.(Arg57Ter). Through contact with clinicians and analysis of other rare reported variants, it was established that these were the same two siblings as in Family A reported previously.1 However, we can now provide follow-up data at ages 27 and 16, allowing the first description of how features of this newly described condition progress into adulthood. The older sibling (Patient 1 from Roos et al.1) continues to have proximal muscle weakness and contractures aged 27, although static rather than progressing into adulthood. However, she has developed respiratory failure since the initial assessment reported by Roos et al.1 Accurate spirometry is limited by restricted mouth opening, but a low forced vital capacity (FVC) worse when supine was noted from adolescence. Overnight pulse oximetry showed some dips in saturations, but was overall satisfactory. More recent deterioration in respiratory function has been noted, and she may be approaching the threshold for non-invasive ventilation. Although there is reported intellectual disability, she works and lives independently. MRI scanning aged 13 demonstrated fatty replacement of gluteus maximus, quadratu

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.